to view the slide as a whole, click here
Age | Sex | Organ | Diagnosis | pTNM | Stage | |||
1 | 66 |
F | breast | infiltrating duct carcinoma | T2N0M0 | IIA |
view at 20X | view at 40X |
2 | 43 |
F | breast | infiltrating duct carcinoma | T3N1M0 | IIIA |
view at 20X | view at 40X |
3 | 58 |
F | breast | infiltrating duct carcinoma | T2N1M0 | IIIA |
view at 20X | view at 40X |
4 | 46 |
F | breast | infiltrating duct carcinoma | T3N1M0 | IIIB |
view at 20X | view at 40X |
5 | 71 |
F | breast | infiltrating papillary carcinoma with signet ring cell | T3N1M0 | IIIA |
view at 20X | view at 40X |
6 | 37 |
F | breast | infiltrating duct carcinoma | T3N1M0 | IIIA |
view at 20X | view at 40X |
7 | 59 |
F | breast | mixed infiltrating duct and lobular carcinoma | T3N1M0 | IIIA |
view at 20X | view at 40X |
8 | 30 |
F | breast | medullary carcinoma | T3N0M0 | IIB |
view at 20X | view at 40X |
9 | 47 |
F | breast | atypical medullary carcinoma | T2N1M0 | IIB |
view at 20X | view at 40X |
10 | 46 |
F | breast | infiltrating duct carcinoma | T3N1M0 | IIIA |
view at 20X | view at 40X |
11 | 32 |
M | liver | combined hepatocellular and cholangiocarcinoma | T3N0M0 | IIIA |
view at 20X | view at 40X |
12 | 57 |
M | liver | hepatocellular carcinoma | T3N0M0 | IIIA |
view at 20X | view at 40X |
13 | 58 |
F | liver | hepatocellular carcinoma | T2N0M0 | II |
view at 20X | view at 40X |
14 | 20 |
M | liver | hepatocellular carcinoma | T4N0M0 | IVA |
view at 20X | view at 40X |
15 | 63 |
F | liver | hepatocellular carcinoma | T2N0M0 | II |
view at 20X | view at 40X |
16 | 66 |
F | liver | hepatocellular carcinoma | T2N0M0 | II |
view at 20X | view at 40X |
17 | 61 |
M | liver | hepatocellular carcinoma | T3N0M0 | IIIA |
view at 20X | view at 40X |
18 | 52 |
M | liver | hepatocellular carcinoma | T3N0M0 | IIIA |
view at 20X | view at 40X |
19 | 50 |
M | liver | combined hepatocellular and cholangiocarcinoma | T3N1M0 | IIIB |
view at 20X | view at 40X |
20 | 56 |
M | liver | hepatocellular carcinoma | T3N0M0 | IIIA |
view at 20X | view at 40X |
21 | 53 |
M | urinary | mucinous adenocarcinoma | view at 20X | view at 40X | ||
22 | 60 |
M | urinary | transitional cell carcinoma | T3bN1M0 | IV |
view at 20X | view at 40X |
23 | 72 |
M | urinary | transitional cell carcinoma | T3bN1M0 | IV |
view at 20X | view at 40X |
24 | 65 |
M | urinary | transitional cell carcinoma | T4aN1M1 | IV |
view at 20X | view at 40X |
25 | 74 |
M | urinary | papillary transitional cell carcinoma | T1N0M0 | I |
view at 20X | view at 40X |
26 | 63 |
F | urinary | papillary transitional cell carcinoma | T1N0M0 | I |
view at 20X | view at 40X |
27 | 58 |
M | urinary | transitional cell carcinoma | T3NxM0 | III |
view at 20X | view at 40X |
28 | 46 |
M | urinary | papillary transitional cell carcinoma | T1N0M0 | I |
view at 20X | view at 40X |
29 | 76 |
M | urinary | transitional cell carcinoma | T3NxM0 | III |
view at 20X | view at 40X |
30 | 63 |
M | urinary | transitional cell carcinoma | T3bN0M0 | III |
view at 20X | view at 40X |
31 | 57 |
F | ovary | papillary serous cystadeno-ca | T3bN1M0 | IIIc |
view at 20X | view at 40X |
32 | 48 |
F | ovary | papillary serous cystadeno-ca, moderately | T3cN0M0 | IIIc |
view at 20X | view at 40X |
33 | 60 |
F | ovary | papillary serous cystadeno-ca, poorly differentitated |
T2cN0M0 | IIc |
view at 20X | view at 40X |
34 | 41 |
F | ovary | papillary serous cystadeno-ca, moderately | T2cN1M0 | IIIc |
view at 20X | view at 40X |
35 | 64 |
F | ovary | papillary serous cystadeno-ca | T3cN0M0 | IIIc |
view at 20X | view at 40X |
36 | 60 |
F | ovary | papillary serous cystadeno-ca | T3cN1M0 | IIIc |
view at 20X | view at 40X |
37 | 54 |
F | ovary | papillary serous cystadeno-ca | T3aN0M0 | IIIa |
view at 20X | view at 40X |
38 | 58 |
F | ovary | papillary serous cystadeno-ca | T2cN0M0 | IIc |
view at 20X | view at 40X |
39 | 16 |
F | ovary | mucinous cystadeno-ca | T1aN0M0 | Ia |
view at 20X | view at 40X |
40 | 57 |
F | ovary | serous cystadeno-ca, poorly differentiated | T3cN0M0 | IIIc |
view at 20X | view at 40X |
41 | 66 |
M | pancreas | ductal ad-ca, moderately differentiated | T4N1aM0 | IVA |
view at 20X | view at 40X |
42 | 63 |
M | pancreas | ductal ad-ca, moderately differentiated | T3N0M0 | II |
view at 20X | view at 40X |
43 | 62 |
M | pancreas | ductal ad-ca, moderately differentiated | T2N1bM0 | III |
view at 20X | view at 40X |
44 | 45 |
M | pancreas | ductal ad-ca, moderately differentiated | T4N1aM0 | IVA |
view at 20X | view at 40X |
45 | 64 |
F | pancreas | ductal ad-ca, moderately differentiated | T4N0M0 | IVA |
view at 20X | view at 40X |
46 | 64 |
F | pancreas | ductal ad-ca, moderately differentiated | T2N1bM0 | III |
view at 20X | view at 40X |
47 | 63 |
M | pancreas | ductal ad-ca, poorly differentiated | T4NxM0 | IVA |
view at 20X | view at 40X |
48 | 46 |
M | pancreas | ductal ad-ca, moderately differentiated | T3N1bM0 | III |
view at 20X | view at 40X |
49 | 54 |
M | pancreas | ductal ad-ca, moderately differentiated | T3N1bM0 | III |
view at 20X | view at 40X |
50 | 40 |
M | pancreas | ductal ad-ca, moderately differentiated | T3N1bM0 | III |
view at 20X | view at 40X |
51 | 85 |
M | prostate | adenocarcinoma | TxNxM1 | IV |
view at 20X | view at 40X |
52 | 79 |
M | prostate | adenocarcinoma | T2aNxM1 | IV |
view at 20X | view at 40X |
53 | 53 |
M | prostate | adenocarcinoma | T2aNxM1 | IV |
view at 20X | view at 40X |
54 | 72 |
M | prostate | adenocarcinoma | TxNxM1 (D2) |
IV |
view at 20X | view at 40X |
55 | 82 |
M | prostate | adenocarcinoma | T2N0M1 | IV |
view at 20X | view at 40X |
56 | 76 |
M | prostate | adenocarcinoma | T3aN0M0 | III |
view at 20X | view at 40X |
57 | 56 |
M | prostate | adenocarcinoma | T2N1M0 | IV |
view at 20X | view at 40X |
58 | 66 |
M | prostate | adenocarcinoma | T4N0M0 | IV |
view at 20X | view at 40X |
59 | 54 |
M | prostate | adenocarcinoma | T1aN0M0 (G2) | I |
view at 20X | view at 40X |
60 | carbon | view at 20X | view at 40X |